Business · 15/05/2008Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for TYZEKA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for TYZEKA's patent extension, as mandated by law, following submissions to the Director of Patents and Trademarks at the US Department of Commerce, regarding human drug products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →